Publication:
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.

Simple item page
dc.contributor.authorFraile-Ribot, Pablo A.
dc.contributor.authorZamorano, Laura
dc.contributor.authorOrellana, Rocio
dc.contributor.authorDel Barrio-Tofiño, Ester
dc.contributor.authorSanchez-Diener, Irina
dc.contributor.authorCortes-Lara, Sara
dc.contributor.authorLopez-Causape, Carla
dc.contributor.authorCabot, Gabriel
dc.contributor.authorBou, German
dc.contributor.authorMartinez-Martinez, Luis
dc.contributor.authorOliver, Antonio
dc.contributor.funderPlan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases
dc.contributor.funderEuropean Regional Development Fund (ERDF)
dc.contributor.funderMSD through Investigator Initiated Studies Program to A.O
dc.contributor.groupGEMARA-SEIMC/REIPI Pseudomonas Study Group
dc.date.accessioned2023-02-08T14:37:36Z
dc.date.available2023-02-08T14:37:36Z
dc.date.issued2019-11-14
dc.description.abstractImipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.
dc.description.sponsorshipThe work was supported by MSD and by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and grant PI18/00076 cofinanced by European Regional Development Fund (ERDF) “A way to achieve Europe,” Operative Program Intelligent Growth 2014 –2020. The work was partially financed by MSD through Investigator Initiated Studies Program to A.O.
dc.identifier.citationFraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, et al. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19
dc.identifier.doi10.1128/AAC.02165-19
dc.identifier.essn1098-6596
dc.identifier.pmcPMC6985745
dc.identifier.pmid31740559
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985745/pdf
dc.identifier.unpaywallURLhttps://europepmc.org/articles/pmc6985745?pdf=render
dc.identifier.urihttp://hdl.handle.net/10668/14708
dc.issue.number2
dc.journal.titleAntimicrobial Agents and Chemotherapy
dc.journal.titleabbreviationAntimicrob Agents Chemother
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.page.number6
dc.provenanceRealizada la curación de contenido 04/06/2025
dc.publisherASM Journals
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.projectIDREIPI RD16/0016)
dc.relation.projectIDPI18/00076
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31740559/
dc.rights.accessRightsRestricted Access
dc.subjectPseudomonas aeruginosa
dc.subjectAntibiotic resistance
dc.subjectExtensively drug resistant
dc.subjectImipenem-relebactam
dc.subjectMultidrug resistance
dc.subjectWhole-genome sequencing
dc.subjectβ-lactam resistance mechanisms
dc.subject.decsAntibacterianos
dc.subject.decsColistina
dc.subject.decsCompuestos de azabiciclo
dc.subject.decsHumanos
dc.subject.decsInfecciones por pseudomonas
dc.subject.decsMutacion
dc.subject.decsPseudomonas aeruginosa
dc.subject.decsResistencia betalactamica
dc.subject.decsbeta-Lactamasas
dc.subject.meshAnti-Bacterial agents
dc.subject.meshAzabicyclo compounds
dc.subject.meshColistin
dc.subject.meshHumans
dc.subject.meshImipenem
dc.subject.meshMutation
dc.subject.meshPseudomonas infections
dc.subject.meshPseudomonas aeruginosa
dc.subject.meshbeta-Lactam Resistance
dc.subject.meshbeta-Lactamases
dc.titleActivity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number64
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
Fraile-Ribot_ActivityOf.pdf
Size:
398.38 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Reina Sofía
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía